Study Details
Design, interventions, and primary outcomes
About This Study
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Design
Interventions / Regimen
- Drug: CDX-622 — Administered Intravenously
Primary Outcomes
- To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma. (Day 1 up to Day 85 (12 weeks))
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-03
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
- Drug: CDX-622 — Administered Intravenously